Women who were treated with E2V for HMB for 3 months.

Women who were treated with LNG-IUD for HMB for 4 years.

Women who were treated with Micronized Progesterone for HMB for 3 months.

Heavy Menstrual Bleeding

Bakirkoy Dr. Sadi Konuk Training and Research Hospital

Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding

Comparison of Estradiol Valerate (E2V), Levonorgestrel- Intrauterine Device (LNG-IUD) and Oral Micronized Progesterone Therapy on Health-related Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding

Hot flush rating scale is a 5 items subjective tool using 1-10 numeric rating scales. Women were asked to provide ratings of the frequency of hot flushes and night sweats in the first and second item. The number of the frequency in the first and second item is summed and this score is the total hot flush frequency score. This score is measured and recorded at initial of the treatment and six months of treatment. The change between the initial and six months score is our first primer outcome.

Hot flush rating scale is a 5 items subjective tool using 1-10 numeric rating scales. The last three items are about problem rating of hot flushes and night sweats. Problem rating is calculated as the mean of the scores on the last three ten point scales assessing the extent to which hot flushes and night sweats are problematic, distressing and causing interference in daily life. Scores for problem rating range between 1 and 10 with higher scores indicating more problematic hot flushes and night sweats.

MRS is a questionnaire that assesses the presence and intensity of 11 menopausal symptoms. These are grouped into three subscales: the somatic subscale, the psychological subscale and the urogenital subscale. Each of the 11 items can be rated by the participant from 0 (not present) to 4 (very severe). The scores obtained for each individual item are summed to provide the corresponding total subscale score. The sum of subscales scores provide the total MRS score. Higher scores are indicative of more severe symptoms. Minimum total MRS score is 0 and maximum total MRS score is 44.The values of total MRS score above 16 were defined as severe.

This is measured by menorrhagia multi-attribute scale; which is designed to measure the effect of menorrhagia on six domains of daily life (practical difficulties, social life, psychological health, physical health, work and daily routine, and family life and relationships). Scores range from 0 (severely affected) to 100 (not affected).

The pictorial blood assessment chart (PBAC) consists of a series of diagrams representing lightly, moderately and heavily soiled towels and tampons.The numbers at the top of the chart represent the day of menstruation. The women are instructed to insert a mark in the appropriate box at the time each towel and/or tampon is discarded.After completion, the woman returns the chart during her next appointment to the clinic.The chart is scored using the scoring system devised by Higham et al. 1990. A baseline score is established and then at six months of treatment the score is assessed again. Change from initial score at 6 months of treatment is recorded as outcome 5. Decreasing values are considered to be a better outcome.

Blood sample analysis for hemoglobin values is performed before the treatment and at six months of treatment.

Ismail Alay

principal investigator

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Postpartum Hemorrhage

Recruiting only pregnant women prior to child-birth delivery.

misoprostol

Queens Hospital Center

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

Effect of Adjunctive Misoprostol on Blood Loss at Vaginal Delivery

Aleksandr Fuks

Directore, Department OB / GYN , Queens Hospital Center

New York City Health and Hospitals Corporation

Postmenopause

Vaginal Atrophy

Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks

Oxytocin

Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks

Placebo

Karolinska University Hospital-Huddinge

Uppsala University Hospital

Northwick Park & St Marks Hospital NHS Trust

Study of Oxytocin to Treat Vaginal Atrophy in Postmenopausal Women

A Double-blind, Placebo Controlled Multi-centre Study to Evaluate the Effects of Topical Oxytocin on Vaginal Atrophy in Postmenopausal Women

The MV describes the change in percentage of superficial cells (Meisels A. The Maturation Value. Acta Cytol. 1967, Jul-Aug;11(4):249)

Atrophy in histological biopsies is assessed by a 4-grade scale

Same as primary outcome but after 2 weeks treatment

The purpose of the evaluation is only to evaluate the systemic uptake. No other PK variables than the concentration are calculated.

Evaluation of seven different features, where every feature is assessed by a 4-grade scale.

Clinical Chemistry, Haematology, Urine analysis, Cervical cytology,Endometrial Histology

Dan Markusson

PepTonic Medical AB

Menopause

DVS-233

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Wyeth is now a wholly owned subsidiary of Pfizer

Traumatic Brain Injury

IV Progesterone

Emory University School of Medicine - Dept. of Emergency Medicine

Progesterone Treatment of Blunt Traumatic Brain Injury

ProTECT: Single Center, Phase II (Pilot), Double Blind, 4:1 Randomized, Placebo Controlled Clinical Trial for Progesterone Treatment of Moderate and Severe Blunt TBI

mastodynia/rith fola

Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

Study of Oxytocin to Treat Vaginal Atrophy in Postmenopausal Women

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Progesterone Treatment of Blunt Traumatic Brain Injury

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht